遺伝性疾患と希少疾患, プレシジョンヘルス, 会社情報, コミュニティー

Highlights from Glasgow: Educating and promoting the impact of WGS

At ESHG 2023, researchers, clinicians, and industry leaders gathered to discuss the practice of genomics

Highlights from Glasgow: Educating and promoting the impact of WGS
2023年6月13日

The Illumina NovaSeq X Plus took center stage at this year's European Society of Human Genetics (ESHG) conference in Glasgow, Scotland, considered Europe’s premier genomics event. Thousands of the world’s leading researchers, clinicians, academics, and pharmaceutical and biotechnology representatives were able to view Illumina’s fastest and most accurate and sustainable sequencer yet. The NovaSeq X Plus made for a fitting display as Illumina celebrates 25 years of innovation, and company representatives were proud to demonstrate the newest sequencer and connect with customers.

Illumina hosted two well-attended workshops with guest speakers from Karolinska University, Tel Aviv University, Radboud University, Broad Institute, and Wellcome Sanger Institute. During the first workshop, “Whole-genome sequencing (WGS) breaking frontiers on patient care,” industry leaders shared the growing benefits of WGS for rare disease. In the second workshop, “Insights from the field on using NovaSeq X Plus System and Illumina Complete Long Reads,” seasoned next-generation sequencing and long-read experts related their firsthand experiences with these transformative technologies.

Recent Articles

大塚製薬株式会社が日本初の保険適用された造血器腫瘍遺伝子パネル検査を発売
大塚製薬株式会社が日本初の保険適用された造血器腫瘍遺伝子パネル検査を発売
研究により、未選択の脳性麻痺の相当な遺伝的起源が明らかになりました
研究により、未選択の脳性麻痺の相当な遺伝的起源が明らかになりました
イルミナのシンガポールチームががんと闘う
イルミナのシンガポールチームががんと闘う